Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer (Solar-Recur)



Status and phase

Phase 3


Biochemical Recurrence of Malignant Neoplasm of Prostate
Prostate Adenocarcinoma
Prostate Cancer


Drug: Copper Cu 64 PSMA I&T

Study type


Funder types




Details and patient eligibility


This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation therapy.

Full description

The study will include approximately 200 patients with suspected biochemically recurrant prostate cancer. Each patient will be administered an 8 mCi (± 10 percent) intravenous dose of copper Cu 64 PSMA I&T injection. PET/CT imaging will be acquired for all patients at 1-4 hours ± 15 minutes post copper Cu 64 PSMA I&T injection. The PET/CT images will be interpreted independently by three readers blinded to all patient information. Each patient study will be assessed and scored for the detection of prostate cancer. Specifically, each reader will categorize images as "Disease" or "No Disease" based only on tumor uptake of copper Cu 64 PSMA-I&T. Analysis of the reads will be used for determination of the patient-level correct detection rate and region-level correct localization rate of copper Cu 64 PSMA I&T PET/CT by comparison to the Reference Standard.


200 estimated patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • Patients with histologically proven prostate adenocarcinoma.

  • Prior radical prostatectomy (greater than 6 weeks prior to screening) or radiation therapy (greater than 1 year prior to screening) with curative intent.

  • Recurrence of disease defined as:

    1. Prior radical prostatectomy: PSA greater than 0.2 ng/mL followed by subsequent confirmatory PSA value greater than 0.2 ng/mL or
    2. Prior radiation therapy: 2 ng/mL rise in PSA over post-treatment nadir.
  • Male aged greater than or equal to 18 years.

  • Able to understand and provide signed written informed consent.

Exclusion criteria

  • Androgen deprivation therapy (ADT) or other therapies targeting the androgen pathway within the past 3 months. Patients with a rising PSA level while on ADT for greater than 6 months are eligible.
  • Patients participating in an interventional clinical trial within 30 days and having received an Investigational Product (IP) within five (5) biological half-lives prior to administration.
  • Patients with any medical condition or circumstance (including receiving an IP or capable of having a PET scan) that the investigator believes may compromise the data collected or lead to a failure to fulfill the study requirements.
  • Patients who are planned to have an x-ray contrast within 24 hours or other PET radiotracer within 10 physical half-lives prior to the PET scan. If Barium contrast is administered this should be cleared before the PET scan.
  • Patients who are administered any high-energy (greater than 300 keV) gamma-emitting radioisotopes within five (5) physical half-lives prior to copper Cu 64 PSMA I&T administration.
  • Patients with known hypersensitivity to the active substance or any of the excipients of the IP.
  • Patients who had a PSMA PET scan as part of their standard medical care within 90 days prior to enrollment.

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

200 participants in 1 patient group

Diagnostic imaging with Copper Cu 64 PSMA I&T
Experimental group
Copper Cu 64 PSMA I&T Injection
Drug: Copper Cu 64 PSMA I&T

Trial contacts and locations



Central trial contact

Darcy Denner, PhD

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems